Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;35(5):1330-1343.
doi: 10.1038/s41375-021-01178-5. Epub 2021 Feb 23.

IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK

Rossana Maffei  1   2 , Stefania Fiorcari  3 , Stefania Benatti  3 , Claudio Giacinto Atene  3 , Silvia Martinelli  3 , Patrizia Zucchini  3 , Leonardo Potenza  3 , Mario Luppi  3 , Roberto Marasca  3
Affiliations

IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK

Rossana Maffei et al. Leukemia. 2021 May.

Abstract

Interferon regulatory factor 4 (IRF4) is a transcriptional regulator of immune system development and function. Here, we investigated the role of IRF4 in controlling responsiveness to B-cell receptor (BCR) stimulation in chronic lymphocytic leukemia (CLL). We modulated IRF4 levels by transfecting CLL cells with an IRF4 vector or by silencing using small-interfering RNAs. Higher IRF4 levels attenuated BCR signaling by reducing AKT and ERK phosphorylation and calcium release. Conversely, IRF4 reduction improved the strength of the intracellular cascade activated by BCR engagement. Our results also indicated that IRF4 negatively regulates the expression of the spleen tyrosine kinase SYK, a crucial protein for propagation of BCR signaling, and the zinc finger DNA-binding protein IKAROS. We modulated IKAROS protein levels both by genetic manipulation and pharmacologically by treating CLL cells with lenalidomide and avadomide (IMIDs). IKAROS promoted BCR signaling by reducing the expression of inositol 5-phosphatase SHIP1. Lastly, IMIDs induced IRF4 expression, while down-regulating IKAROS and interfered with survival advantage mediated by BCR triggering, also in combination with ibrutinib. Overall, our findings elucidate the mechanism by which IRF4 tunes BCR signaling in CLL cells. Low IRF4 levels allow an efficient transmission of BCR signal throughout the accumulation of SYK and IKAROS.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Regulatory effects of IRF4 on immune cells in the tumor microenvironment.
    Lu J, Liang T, Li P, Yin Q. Lu J, et al. Front Immunol. 2023 Feb 6;14:1086803. doi: 10.3389/fimmu.2023.1086803. eCollection 2023. Front Immunol. 2023. PMID: 36814912 Free PMC article. Review.
  • Molecular interactions of IRF4 in B cell development and malignancies.
    Sundararaj S, Casarotto MG. Sundararaj S, et al. Biophys Rev. 2021 Aug 13;13(6):1219-1227. doi: 10.1007/s12551-021-00825-6. eCollection 2021 Dec. Biophys Rev. 2021. PMID: 35059038 Free PMC article. Review.
  • Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.
    Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, Dawson KJ, Kulis M, Diaz-Navarro A, Villamor N, Melero JL, Chapaprieta V, Dueso-Barroso A, Delgado J, Moia R, Ruiz-Gil S, Marchese D, Giró A, Verdaguer-Dot N, Romo M, Clot G, Rozman M, Frigola G, Rivas-Delgado A, Baumann T, Alcoceba M, González M, Climent F, Abrisqueta P, Castellví J, Bosch F, Aymerich M, Enjuanes A, Ruiz-Gaspà S, López-Guillermo A, Jares P, Beà S, Capella-Gutierrez S, Gelpí JL, López-Bigas N, Torrents D, Campbell PJ, Gut I, Rossi D, Gaidano G, Puente XS, Garcia-Roves PM, Colomer D, Heyn H, Maura F, Martín-Subero JI, Campo E. Nadeu F, et al. Nat Med. 2022 Aug;28(8):1662-1671. doi: 10.1038/s41591-022-01927-8. Epub 2022 Aug 11. Nat Med. 2022. PMID: 35953718 Free PMC article.
  • IKAROS expression drives the aberrant metabolic phenotype of macrophages in chronic HIV infection.
    Vittori C, Faia C, Wyczechowska D, Trauth A, Plaisance-Bonstaff K, Meyaski-Schluter M, Reiss K, Peruzzi F. Vittori C, et al. Clin Immunol. 2024 Mar;260:109915. doi: 10.1016/j.clim.2024.109915. Epub 2024 Jan 28. Clin Immunol. 2024. PMID: 38286172
  • The dynamic functions of IRF4 in B cell malignancies.
    Maffei R, Fiorcari S, Atene CG, Martinelli S, Mesini N, Pilato F, Lagreca I, Barozzi P, Riva G, Nasillo V, Paolini A, Forghieri F, Potenza L, Trenti T, Tagliafico E, Luppi M, Marasca R. Maffei R, et al. Clin Exp Med. 2023 Aug;23(4):1171-1180. doi: 10.1007/s10238-022-00968-0. Epub 2022 Dec 10. Clin Exp Med. 2023. PMID: 36495369 Free PMC article. Review.
See all "Cited by" articles

References

    1. Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol. 2008;29:487–92. - PubMed - PMC - DOI
    1. Ma S, Pathak S, Trinh L, Lu R. Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. Blood. 2008;111:1396–403. - PubMed - PMC - DOI
    1. Ochiai K, Maienschein-Cline M, Simonetti G, Chen J, Rosenthal R, Brink R, et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity. 2013;38:918–29. - PubMed - PMC - DOI
    1. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25:225–36. - PubMed - DOI
    1. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40:1204–10. - PubMed - DOI

Publication types

MeSH terms

LinkOut - more resources